C-8TN3General Control
epigenetic editing, gene activation, programmable therapies
editinggene editing
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8TN3
C-8TN3C-8TN3epigenetic editing, gene activation, programmable therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
General Control Biotechnologies states that age-related diseases are complex, involving many interacting phenotypes, and argues that the traditional one-molecule/one-protein drug model has not meaningfully slowed or reversed conditions like Alzheimer's or sarcopenia. The company presents multiplexed epigenetic editors as a better approach because they can programmably rewrite gene expression and coordinate locus-specific control of multiple genes or disease-network nodes within a single therapy, with the goal of restoring gene expression to a healthy baseline.
SourceGeneral Control states that age-related diseases such as Alzheimer’s and sarcopenia are too complex for the traditional one-molecule-one-protein drug model, and that better therapies will come from programmable epigenetic medicines that can rewrite multiple genes’ expression at once and restore gene expression toward a healthy baseline.
Source